| Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial P McGuire, P Robson, WJ Cubala, D Vasile, PD Morrison, R Barron, ... American Journal of Psychiatry 175 (3), 225-231, 2018 | 657 | 2018 |
| Quality of life impairments and stress coping strategies during the COVID-19 pandemic isolation and quarantine—A Web-based survey O Vasiliu, D Vasile, DG Vasiliu, OM Ciobanu Rom. J. Military Med 124 (1), 10-21, 2021 | 16 | 2021 |
| Cognitive-behavioral therapy for internet gaming disorder and alcohol use disorder-A case report O Vasiliu, D Vasile International Journal of Psychiatry and Psychotherapy 2, 34-38, 2017 | 13 | 2017 |
| Analysis of risk factors for antipsychotic-resistant schizophrenia in young patients-a retrospective analysis O Vasiliu, D Vasile, AF Făinărea, MC Pătrașcu, EA Morariu, R Manolache, ... Romanian Journal of Military Medicine 121 (1), 25-29, 2018 | 12 | 2018 |
| Efficacy and tolerability of antibiotic augmentation in schizophrenia spectrum disorders-A systematic literature review O Vasiliu, D Vasile, V Voicu Rom J Military Med 123, 3-20, 2020 | 11 | 2020 |
| P. 2. f. 008 SSRI dose escalation versus duloxetine in treatment of major depressive disorder not responding to initial SSRI B Petrescu, D Vasile, O Vasiliu, C Tudor, A Mangalagiu, D Ungureanu European Neuropsychopharmacology, S455-S456, 2014 | 11 | 2014 |
| Translational approaches in treatment-resistant depression based on animal model I Marinescu, O Vasiliu, D Vasile Rom J Morphol Embryol 59 (3), 955-964, 2018 | 10 | 2018 |
| A double-blind, randomised, placebo-controlled, parallel group trial of cannabidiol as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder P McGuire, P Robson, WJ Cubala, D Vasile, PD Morrison, S Wright 5th Schizophrenia International Research Society Conference, Florence, 2016 | 10 | 2016 |
| P. 2. c. 002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus D Vasile, O Vasiliu, ML Vasile, M Terpan, DG Ojog European Neuropsychopharmacology, S383-S384, 2011 | 10 | 2011 |
| An open-label tolerability study of BL-1020 antipsychotic: a novel gamma aminobutyric acid ester of perphenazine R Anand, Y Geffen, D Vasile, I Dan Clinical neuropharmacology 33 (6), 297-302, 2010 | 9 | 2010 |
| Efficacy and tolerability of calcium channel alpha-2-delta ligands in psychiatric disorders O Vasiliu, D Vasile, AG Mangalagiu, BM Petrescu, C Tudor, D Ungureanu, ... Rom J Military Med 120, 27-31, 2017 | 8 | 2017 |
| Risk factors and quality of life in late-life depressive disorders O Vasiliu, D Vasile Rom J Military Med 119, 24-28, 2016 | 8 | 2016 |
| Antisocial personality disorder-heroin-dependence comorbidity D Vasile, MD Gheorghe, R Ciurea, S Paraschiv European Neuropsychopharmacology, 392, 2002 | 7 | 2002 |
| Self-perception of quality of life in patients treated with antipsychotics L Dima, D Vasile, L ROGOZAE, M Zia-Ul-Haq, SA Bukhari, M Moga Turkish Journal of Medical Sciences 45 (4), 782-788, 2015 | 6 | 2015 |
| P. 3. c. 014 Side effects of atypical antipsychotics-prediction factor for compliance A Baloescu, D Vasile, MD Gheorghe, G Grigorescu European Neuropsychopharmacology, S404, 2006 | 6 | 2006 |
| Current treatment of posttraumatic stress disorder—A review of therapeutic guidelines and good practice recommendations O Vasiliu, D Vasile, AG Mangalagiu, MB Petrescu, CA Candea, C Tudor, ... RJMM 123, 241-248, 2020 | 5 | 2020 |
| COMPARATIVE DISCONTINUATION RATES IN PATIENTS TREATED WITH ANTIPSYCHOTICS. D Lorena, D Vasile, VA Voicu Therapeutics, Pharmacology & Clinical Toxicology 16 (3), 2012 | 5 | 2012 |
| Diagnostic and treatment features of work stressrelated disorders in healthcare professionals in the context of COVID-19 pandemic. O Vasiliu, I Marinescu, D Vasile Psihiatru. ro 66 (3), 2021 | 4 | 2021 |
| 17.1 A randomized controlled trial of cannabidiol in schizophrenia P McGuire, P Robson, W Cubała, D Vasile, P Morrison, R Barron, A Taylor, ... Schizophrenia Bulletin 44 (Suppl 1), S27, 2018 | 4 | 2018 |
| P. 3. d. 028 Effectiveness and tolerability of nalmefene in alcohol use dependence comorbid with schizophrenia D Vasile, O Vasiliu, GA Sopterean, RE Bratu, F Androne, F Vasile European Neuropsychopharmacology, S538, 2014 | 4 | 2014 |
